Impact of tisagenlecleucel product attributes on clinical outcomes in pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia (r/r ALL).

被引：0
|
作者：
Gershgorin, Irina [1 ]
Waldron, Edward R. [1 ]
Grupp, Stephan A. [2 ]
Levine, John E. [3 ]
Pulsipher, Michael A. [4 ]
Davies, Stella M. [5 ]
Myers, G. Doug [6 ]
Jeschke, Margit [7 ]
Engels, Boris [8 ]
del Corral, Chris [1 ]
Baruchel, Andre [9 ,10 ]
机构：
[1] Novartis Pharmaceut, E Hanover, NJ USA
[2] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
[3] Univ Michigan, Ann Arbor, MI 48109 USA
[4] Childrens Hosp Los Angeles, Keck Sch Med USC, Los Angeles, CA 90027 USA
[5] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA
[6] Childrens Mercy Hosp, Kansas City, MO 64108 USA
[7] Novartis Pharma AG, Basel, Switzerland
[8] Novartis Inst BioMed Res, Cambridge, MA USA
[9] Hop Univ Robert Debre, AP HP, Paris, France
[10] Univ Paris, Paris, France
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
510
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia
    Grupp, Stephan A.
    Maude, Shannon L.
    Rives, Susana
    Baruchel, Andre
    Boyer, Michael W.
    Bittencourt, Henrique
    Bader, Peter
    Buchner, Jochen
    Laetsch, Theodore W.
    Stefanski, Heather
    Myers, Gary Douglas
    Qayed, Muna
    Pulsipher, Michael A.
    De Moerloose, Barbara
    Yanik, Gregory A.
    Davis, Kara L.
    Martin, Paul L.
    Nemecek, Eneida R.
    Peters, Christina
    Krueger, Joerg
    Balduzzi, Adriana
    Boissel, Nicolas
    Mechinaud, Francoise Marie
    Leung, Mimi
    Eldjerou, Lamis K.
    Yi, Lan
    Mueller, Karen Thudium
    Bleickardt, Eric
    Hiramatsu, Hidefumi
    BLOOD, 2018, 132
  • [2] Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL).
    Bhojwani, Deepa
    Sposto, Richard
    Shah, Nirali
    Rodriguez, Vilmarie
    O'Brien, Maureen Megan
    McNeer, Jennifer Lynn
    Loh, Mignon L.
    Rheingold, Susan R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia
    Laetsch, Theodore W.
    Maude, Shannon L.
    Balduzzi, Adriana
    Rives, Susana
    Bittencourt, Henrique
    Boyer, Michael W.
    Buechner, Jochen
    De Moerloose, Barbara
    Qayed, Muna
    Phillips, Christine L.
    Pulsipher, Michael A.
    Hiramatsu, Hidefumi
    Tiwari, Ranjan
    Grupp, Stephan A.
    LEUKEMIA, 2022, 36 (06) : 1508 - 1515
  • [4] Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia
    Theodore W. Laetsch
    Shannon L. Maude
    Adriana Balduzzi
    Susana Rives
    Henrique Bittencourt
    Michael W. Boyer
    Jochen Buechner
    Barbara De Moerloose
    Muna Qayed
    Christine L. Phillips
    Michael A. Pulsipher
    Hidefumi Hiramatsu
    Ranjan Tiwari
    Stephan A. Grupp
    Leukemia, 2022, 36 : 1508 - 1515
  • [5] Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: Updated Analysis of the ELIANA Clinical Trial
    Grupp, Stephan A.
    Maude, Shannon L.
    Rives, Susana
    Baruchel, Andre
    Boyer, Michael
    Bittencourt, Henrique
    Bader, Peter
    Buchner, Jochen
    Laetsch, Theodore W.
    Stefanski, Heather
    Myers, Gary Douglas
    Qayed, Muna
    Pulsipher, Michael A.
    De Moerloose, Barbara
    Yanik, Gregory A.
    Davis, Kara L.
    Martin, Paul L.
    Nemecek, Eneida R.
    Peters, Christina
    Krueger, Joerg
    Balduzzi, Adriana, Sr.
    Boissel, Nicolas
    Mechinaud, Francoise
    Leung, Mimi
    Eldjerou, Lamis
    Bleickardt, Eric
    Mueller, Karen Thudium
    Hiramatsu, Hidefumi
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [6] CTL019 Clinical Pharmacology and Biopharmaceutics in Pediatric Patients with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
    Mueller, Karen Thudium
    Waldron, Edward
    Grupp, Stephan A.
    Levine, John
    Laetsch, Theodore W.
    Pulsipher, Michael A.
    Boyer, Michael
    August, Keith
    Hamilton, Jason
    Awasthi, Rakesh
    Sickert, Denise
    Chakraborty, Abhijit
    Levine, Bruce L.
    June, Carl H.
    Tomassian, Lori
    Leung, Mimi
    Taran, Tetiana
    Wood, Patricia
    Maude, Shannon
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S261 - S262
  • [7] Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia
    Hidefumi Hiramatsu
    Souichi Adachi
    Katsutsugu Umeda
    Itaru Kato
    Lamis Eldjerou
    Andrea Chassot Agostinho
    Kazuto Natsume
    Kota Tokushige
    Yoko Watanabe
    Stephan A. Grupp
    International Journal of Hematology, 2020, 111 : 303 - 310
  • [8] Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia
    Hiramatsu, Hidefumi
    Adachi, Souichi
    Umeda, Katsutsugu
    Kato, Itaru
    Eldjerou, Lamis
    Agostinho, Andrea Chassot
    Natsume, Kazuto
    Tokushige, Kota
    Watanabe, Yoko
    Grupp, Stephan A.
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (02) : 303 - 310
  • [9] CTL019 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS IN PEDIATRIC PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
    Mueller, K. Thudium
    Waldron, E.
    Grupp, S. A.
    Levine, J.
    Laetsch, T. W.
    Pulsipher, M. A.
    Boyer, M.
    August, K.
    Hamilton, J.
    Awasthi, R.
    Sickert, D.
    Chakraborty, A.
    Levine, B. L.
    June, C. H.
    Tomassian, L.
    Leung, M.
    Taran, T.
    Wood, P.
    Maude, S. L.
    HAEMATOLOGICA, 2017, 102 : 178 - 179
  • [10] Inotuzumab Ozogamicin (Besponsa®) for Patients with relapsed or refractory acute lymphoblastic Leukemia (r/r ALL)
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (1-2) : 66 - 66
12345